Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aspirin with Neoadjuvant Chemotherapy in Ovarian, Fallopian Tube, or Peritoneal Carcinoma
NCT05080946Phase 1Suspended
- Sponsor
- Moffitt Cancer Center
- Start
- Nov 2021
- Primary completion
- Nov 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) comparing Aspirin + Chemotherapy with Placebo + Chemotherapy (2 arms). Primary endpoints: Change in intratumoral density of immunosuppressive T-regulatory (FOXP3+) cells at 5 months and Change in intratumoral density of M2 tumor-associated macrophages (CD163+ cells) at 5 months. Started Nov 2021; status: suspended.
02
Drugs
aspirin
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT05080946.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05080946.